Analysed CONNECT BIOPHARMA HOLDINGS L (CNTB:NASDAQ) News Sources
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
12-05-2026
yahoo.com
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
12-08-2026
yahoo.com
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
03-09-2026
yahoo.com
Connect Biopharma Rademikibart Phase 2 Data Shows Lung Function Improvement but Primary Endpoint Misses Significance
15-09-2026
advfn.com
Connect Biopharma (CNTB) Misses Key Asthma Trial Goal. Can its Drug Still Move Forward?
22-09-2026
yahoo.com
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
30-09-2026
yahoo.com
Connect Biopharma Reports Positive Phase 2 Rademikibart COPD Data, Plans FDA Talks on Phase 3 Program
30-09-2026
advfn.com
Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher
19-10-2026
yahoo.com
What is the current price of CONNECT BIOPHARMA HOLDINGS L (CNTB:NASDAQ)?
The current price of CONNECT BIOPHARMA HOLDINGS L (CNTB:NASDAQ) is $0.8022.
CONNECT BIOPHARMA HOLDINGS L (CNTB:NASDAQ) absolute price change since previous trading day?
The absolute price change of CONNECT BIOPHARMA HOLDINGS L (CNTB:NASDAQ) since the previous trading day is $-0.0332.
CONNECT BIOPHARMA HOLDINGS L (CNTB:NASDAQ) percentage price change since previous trading day?
The percentage price change of CONNECT BIOPHARMA HOLDINGS L (CNTB:NASDAQ) since the previous trading day is -3.9741%.
What is the most recent average sentiment score for CONNECT BIOPHARMA HOLDINGS L (CNTB:NASDAQ)?
The most recent average sentiment score for CONNECT BIOPHARMA HOLDINGS L (CNTB:NASDAQ) is 74 out of 100.
What is the most recent average sentiment for CONNECT BIOPHARMA HOLDINGS L (CNTB:NASDAQ)?
The most recent sentiment for CONNECT BIOPHARMA HOLDINGS L (CNTB:NASDAQ) is .
SEC-8K** Filing Available For CONNECT BIOPHARMA HOLDINGS L (CNTB:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.